The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Achaogen | Common Stock | 004449104 | 4,701 | 481,694 | SH | SOLE | 481,694 | 0 | 0 | ||
| Dicerna Pharmaceuticals | Common Stock | 253031108 | 8,661 | 360,447 | SH | SOLE | 360,447 | 0 | 0 | ||
| Egalet | Common Stock | 28226B104 | 34,207 | 2,645,558 | SH | SOLE | 2,645,558 | 0 | 0 | ||
| FibroGen | Common Stock | 31572Q808 | 30,506 | 972,175 | SH | SOLE | 972,175 | 0 | 0 | ||
| Juno Therapeutics | Common Stock | 48205A109 | 83,407 | 1,375,000 | SH | SOLE | 1,375,000 | 0 | 0 | ||
| Paratek Pharmaceuticals | Common Stock | 699374302 | 66,861 | 2,138,872 | SH | SOLE | 2,138,872 | 0 | 0 | ||
| Proteon Therapeutics | Common Stock | 74371L109 | 2,907 | 250,000 | SH | SOLE | 250,000 | 0 | 0 | ||